https://revistas.ufps.edu.co/index.php/covalente <p>Covalente es una revista científica de Matemáticas, Arquitectura, y ciencias afines, abierta a la comunidad nacional e internacional, que recibe artículos indistintamente en lengua española e inglesa. Los autores tienen a su disposición toda la información necesaria para adaptar el formato y estilo de su manuscrito a la revista, así como la descripción del proceso de envío Revista Científica de Matemáticas, Arquitectura, y ciencias afines, es una publicación bilingüe de los Grupos de investigación de los programas de Maestría en Educación Matemática y Arquitectura: Euler, Graunt, Arquímedes, DiLab, Target, Grama, establecidos desde 1999 y su Centro de Consultoría en Estadística. Se edita desde 2019, actualmente con una periodicidad fija semestral.</p> Universidad Francisco de Paula Santander es-ES Covalente 2711-015X <h4 align="center">La Revista ofrece Acceso Abierto bajo una licencia Creative Commons Attibution License<img src="https://revistas.ufps.edu.co/index.php/covalente/management/settings/distribution//index.php/perspectivas/management/settings/distribution//ojs/public/site/images/ojsadmin/88x312.png" alt="" align="center" /></h4> <p align="center">Esta obra está bajo una <a href="http://creativecommons.org/licenses/by/4.0/" rel="license">Licencia Creative Commons Atribución-NoComercial 4.0 Internacional</a>.</p> https://revistas.ufps.edu.co/index.php/covalente/article/view/3456 <p><span style="font-weight: 400;">HPV infection is one of the most prevalent sexually transmitted diseases, annually 80% of sexually active persons are infected by this virus at some time in their lives. In recent years, various bacteria such as Escherichia coli have been used to produce HPV L1 VLP vaccine instead of expensive eukaryotic systems. Considering that a key feature of L1 is its high immunogenicity, the aim of this work was to simulate a production plant of this protein from E. coli by proposing a bioprocess that allows cost reduction which could be used in other research for the analysis of HPV vaccine performance. The production plant was simulated using SuperPro Designer® v10.0 software. From the analyses of the simulation of the manufacturing process and the reports on the overall costs of the system, it is possible to determine that the annual costs are estimated at approximately 32 million USD, also, the cost result allows inferring that each dose would have a value of 0.19 USD/unit, being the most relevant component the manufacturing operating cost.</span></p> Giovanny Mantilla Parada Diana Gabriela Vega Copyright (c) 2022 https://creativecommons.org/licenses/by-nc/4.0/deed.es 2020-06-01 2020-06-01 3 1 10.22463/2711015X.3456